Abstract
Aim: This study investigated the lifestyle convenience of Insulin therapy for adult women patients with type 1 diabetes. Methods: Participants were type 1 diabetes adult women patients who switched from multiple daily injection (MDI) therapy to Continuous Subcutaneous Insulin Infusion (CSII) therapy. We conducted semi-structured interviews with participants. To analyze, we referenced the classification table of Hamada’s study comparing the usefulness of both the NovoPen? and CSII. Semi-structured interviews were conducted with the research subjects. The questions focused mainly on diabetes management, instrument operation, everyday life, and social, psychological and lifestyle convenience aspects during MDI and CSII. Results: Research subjects were 4 women patients with type 1 diabetes. The average age was 35.3 ± 6.24 (SE) years old. Participants were undergoing MDI therapy; however, in the middle, they switched to CSII therapy. CSII therapy is convenient in terms of diabetes management, social and psychological. MDI therapy is convenient in terms of instrument operation and daily life. Compared to MDI therapy, CSII therapy is less convenient in terms of instrument operation and everyday life. However, since CSII therapy has more stable HbA1c and blood glucose levels compared to MDI therapy, it is more convenient in terms of social and psychological aspects and reduces those burdens. About economy CSII therapy, patients paid about 5000 yen more per month compared to MDI therapy. Conclusion: It is believed that patients prioritize therapeutic effects, and choose CSII, which is stable in psychological and social aspects, even though it is inconvenient with life.
Highlights
For type 1 diabetes treatment, there is Multiple Daily Injection (MDI) therapy and Continuous Subcutaneous Insulin Infusion (CSII) therapy
We report on our comparative examination of instrument operation, diabetes management, everyday life, and social, and psychological aspects based on 4 cases of type 1 diabetes female patients who experienced both multiple daily injection (MDI) and CSII therapy
Research subjects were undergoing MDI therapy; in the middle, they switched to CSII therapy, because CSII had the advantage of infusing insulin continuously into the participants’ body
Summary
For type 1 diabetes treatment, there is Multiple Daily Injection (MDI) therapy and Continuous Subcutaneous Insulin Infusion (CSII) therapy. Insulin pump improvement has progressed, and type 1 diabetes patients introduced to CSII therapy are increasing. In the Diabetes Control and Complication Trial [1], reported in 1998, the effectiveness of CSII therapy was reported. Since the amount of insulin can be adjusted to match the patient’s lifestyle, the greatest benefit of CSII therapy is that it stabilizes fluctuations in blood glucose and can reduce the risk of severe hypoglycemia [2]-[6]. For Japanese CSII therapy subjects, it can be adapted for type 1 diabetes patients for whom glycemic control was poor in MDI therapy, as well as for patients who are pregnant or wish to be pregnant and give birth. Limitations are applied to the patient’s actions, and it becomes necessary to spend time and effort adapting to the lifestyle changes
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
